- Home
- CHRS vs LFT Comparison
CHRS vs LFT Comparison
Compare CHRS & LFT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CHRS
- LFT
- Stock Information
- Founded
- CHRS 2010
- LFT 2012
- Country
- CHRS United States
- LFT United States
- Employees
- CHRS N/A
- LFT N/A
- Industry
- CHRS Biotechnology: Biological Products (No Diagnostic Substances)
- LFT Real Estate Investment Trusts
- Sector
- CHRS Health Care
- LFT Real Estate
- Exchange
- CHRS Nasdaq
- LFT Nasdaq
- Market Cap
- CHRS 112.5M
- LFT 125.6M
- IPO Year
- CHRS 2014
- LFT N/A
- Fundamental
- Price
- CHRS $0.76
- LFT $2.59
- Analyst Decision
- CHRS Buy
- LFT Hold
- Analyst Count
- CHRS 3
- LFT 2
- Target Price
- CHRS $4.68
- LFT N/A
- AVG Volume (30 Days)
- CHRS 1.2M
- LFT 109.3K
- Earning Date
- CHRS 08-07-2025
- LFT 05-12-2025
- Dividend Yield
- CHRS N/A
- LFT 15.83%
- EPS Growth
- CHRS N/A
- LFT N/A
- EPS
- CHRS N/A
- LFT 0.20
- Revenue
- CHRS $272,251,000.00
- LFT $27,066,283.00
- Revenue This Year
- CHRS N/A
- LFT $152.58
- Revenue Next Year
- CHRS $132.69
- LFT N/A
- P/E Ratio
- CHRS $1.79
- LFT $13.01
- Revenue Growth
- CHRS 19.87
- LFT N/A
- 52 Week Low
- CHRS $0.66
- LFT $2.22
- 52 Week High
- CHRS $2.43
- LFT $2.84
- Technical
- Relative Strength Index (RSI)
- CHRS 40.42
- LFT 54.94
- Support Level
- CHRS $0.74
- LFT $2.52
- Resistance Level
- CHRS $0.90
- LFT $2.65
- Average True Range (ATR)
- CHRS 0.05
- LFT 0.07
- MACD
- CHRS 0.01
- LFT 0.02
- Stochastic Oscillator
- CHRS 13.56
- LFT 77.78
About CHRS Coherus BioSciences Inc.
Coherus BioSciences Inc is a commercial-stage biopharmaceutical company building an immuno-oncology franchise funded with cash generated by its diversified portfolio of FDA-approved therapeutics. The company is focused on the research, development, and commercialization of its portfolio of FDA-approved oncology products, including LOQTORZI. The company markets UDENYCA, a biosimilar of Neulasta in the United States, and expects to launch the FDA-approved Humira biosimilar YUSIMRY in the United States in 2023. The company generates revenue from the United States.
About LFT Lument Finance Trust Inc.
Lument Finance Trust Inc operates as a real estate investment trust. The company is engaged in investment, financing, and management of a portfolio of commercial real estate debt investments. It invests in transitional floating-rate commercial real estate mortgage loans, mezzanine loans, preferred equity, commercial mortgage-backed securities, fixed-rate loans, construction loans, and other CRE debt instruments.